FDA priority review
The latest news about FDA priority review: headlines, AI summaries and the full story from every source.
- Palvella Therapeutics Reports Q3 GAAP EPS of -$1.70, Exceeding Estimates
- uniQure Receives FDA Priority Review for AMT-130 with PDUFA Date Set for May 2027
- FDA Grants Priority Review for uniQure's Huntington's Disease Gene Therapy
- FDA Grants Priority Review to Palvella Therapeutics' Qtorin Rapamycin Application